Perrigo Company plc (PRGO) 10-Year Financial Performance & Capital Metrics

PRGO • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

AboutPerrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.Show more

Revenue $4.37B -6.1%
EBITDA $439M -14.2%
Net Income -$172M -1252.8%
EPS (Diluted) -1.25 -1231.2%
Gross Margin 35.27% -2.3%
EBITDA Margin 10.03% -8.7%
Operating Margin 2.58% -20.9%
Net Margin -3.93% -1340.0%
ROE -3.78% -1330.6%
ROIC 1.09% -20.0%
Debt/Equity 0.84 -2.0%
Interest Coverage 0.60 -31.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.74%

5Y2.48%

3Y1.86%

TTM-2.51%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM67.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM66.89%

ROCE

10Y Avg1.15%

5Y Avg2.13%

3Y Avg1.23%

Latest1.27%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.73B	9.82	30.69	-0.61%	11.72%	16.31%	4.69%	0.62
UPCUniverse Pharmaceuticals Inc.	2.35M	4.17	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	837.58K	0.20	-0.08	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	17.48M	0.47	-0.40	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.07B	15.06	-12.05	-6.06%	-1.21%	-1.17%	11.8%	0.84

Profit & Loss

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.6B	5.28B	4.95B	4.73B	3.87B	4.09B	4.14B	4.45B	4.66B	4.37B
Revenue Growth %	0.13%	0.15%	-0.06%	-0.04%	-0.18%	0.06%	0.01%	0.08%	0.05%	-0.06%
Cost of Goods Sold+	2.89B	3.23B	2.97B	2.9B	2.44B	2.59B	2.72B	3B	2.98B	2.83B
COGS % of Revenue	0.63%	0.61%	0.6%	0.61%	0.63%	0.63%	0.66%	0.67%	0.64%	0.65%
Gross Profit+	1.71B	2.05B	1.98B	1.83B	1.43B	1.49B	1.42B	1.46B	1.68B	1.54B
Gross Margin %	0.37%	0.39%	0.4%	0.39%	0.37%	0.37%	0.34%	0.33%	0.36%	0.35%
Gross Profit Growth %	0.18%	0.2%	-0.04%	-0.07%	-0.22%	0.04%	-0.05%	0.03%	0.15%	-0.08%
Operating Expenses+	959.6M	1.39B	1.27B	1.35B	1.26B	1.23B	1.01B	1.38B	1.53B	1.43B
OpEx % of Revenue	0.21%	0.26%	0.26%	0.29%	0.33%	0.3%	0.24%	0.31%	0.33%	0.33%
Selling, General & Admin	771.8M	1.21B	1.15B	1.13B	1.1B	1.11B	1.11B	1.21B	1.27B	1.11B
SG&A % of Revenue	0.17%	0.23%	0.23%	0.24%	0.28%	0.27%	0.27%	0.27%	0.27%	0.25%
Research & Development	187.8M	184M	167.7M	218.6M	119.2M	121.7M	122M	123.1M	122.5M	112.2M
R&D % of Revenue	0.04%	0.03%	0.03%	0.05%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%
Other Operating Expenses	0	0	10.1M	-6.1M	42.6M	-1.1M	-227.6M	43.3M	131.4M	205M
Operating Income+	747.6M	-2B	598.2M	236.5M	174.7M	265.2M	410.4M	78.9M	151.9M	112.9M
Operating Margin %	0.16%	-0.38%	0.12%	0.05%	0.05%	0.06%	0.1%	0.02%	0.03%	0.03%
Operating Income Growth %	0.32%	-3.67%	1.3%	-0.6%	-0.26%	0.52%	0.55%	-0.81%	0.93%	-0.26%
EBITDA+	1.3B	-1.54B	1.04B	660.1M	571.2M	650M	722.6M	417.5M	511.4M	438.8M
EBITDA Margin %	0.28%	-0.29%	0.21%	0.14%	0.15%	0.16%	0.17%	0.09%	0.11%	0.1%
EBITDA Growth %	0.4%	-2.19%	1.68%	-0.37%	-0.13%	0.14%	0.11%	-0.42%	0.22%	-0.14%
D&A (Non-Cash Add-back)	548.8M	457M	444.8M	423.6M	396.5M	384.8M	312.2M	338.6M	359.5M	325.9M
EBIT	389.5M	-4.63B	453.5M	419.6M	265.5M	133.6M	383.7M	16.9M	165.5M	107.1M
Net Interest Income+	-155.7M	-218.8M	-173.4M	-129M	-126.5M	-127.7M	-125M	-156M	-173.8M	-187.8M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	155.7M	218.8M	173.4M	129M	126.5M	127.7M	125M	156M	173.8M	187.8M
Other Income/Expense	-499.6M	-2.85B	-318.1M	54.1M	-26.7M	-259.3M	-151.7M	-218M	-160.2M	-193.6M
Pretax Income+	248M	-4.85B	280.1M	290.6M	148M	5.9M	258.7M	-139.1M	-8.3M	-80.7M
Pretax Margin %	0.05%	-0.92%	0.06%	0.06%	0.04%	0%	0.06%	-0.03%	-0%	-0.02%
Income Tax+	120.1M	-835.5M	160.5M	159.6M	-10.7M	-38.3M	389.6M	-8.2M	-3.9M	80M
Effective Tax Rate %	0.52%	0.83%	0.43%	0.45%	0.99%	-27.56%	-0.27%	1.01%	1.53%	2.13%
Net Income+	127.9M	-4.01B	119.6M	131M	146.1M	-162.6M	-68.9M	-140.6M	-12.7M	-171.8M
Net Margin %	0.03%	-0.76%	0.02%	0.03%	0.04%	-0.04%	-0.02%	-0.03%	-0%	-0.04%
Net Income Growth %	-0.38%	-32.37%	1.03%	0.1%	0.12%	-2.11%	0.58%	-1.04%	0.91%	-12.53%
Net Income (Continuing)	85M	-4.01B	119.6M	131M	158.7M	44.2M	-130.9M	-130.9M	-4.4M	-160.7M
Discontinued Operations	0	0	0	0	-12.6M	-206.8M	62M	-9.7M	-8.3M	-11.1M
Minority Interest	-600K	-500K	100K	100K	300K	0	0	0	0	0
EPS (Diluted)+	0.91	-28.00	0.84	0.95	1.07	-1.19	-0.98	-0.97	-0.09	-1.25
EPS Growth %	-0.49%	-31.77%	1.03%	0.13%	0.13%	-2.11%	0.18%	0.01%	0.9%	-12.31%
EPS (Basic)	0.92	-28.01	0.84	0.95	1.07	-1.19	-0.98	-0.97	-0.09	-1.25
Diluted Shares Outstanding	139.8M	143.3M	142.6M	138.3M	136.5M	136.1M	133.6M	134.5M	135.3M	137.4M
Basic Shares Outstanding	139.3M	143.26M	142.3M	137.8M	136M	136.1M	133.6M	134.5M	135.3M	137.4M
Dividend Payout Ratio	0.56%	-	0.76%	0.8%	0.77%	-	-	-	-	-

Balance Sheet

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.74B	2.81B	2.82B	2.9B	2.73B	3.13B	3.86B	2.72B	2.83B	2.48B
Cash & Short-Term Investments	417.8M	622.3M	678.7M	551.1M	354.3M	631.5M	1.86B	600.7M	751.3M	558.8M
Cash Only	417.8M	622.3M	678.7M	551.1M	354.3M	631.5M	1.86B	600.7M	751.3M	558.8M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.19B	1.18B	1.13B	1.07B	1.24B	593.5M	652.9M	697.1M	739.6M	642.3M
Days Sales Outstanding	94.59	81.29	83.45	82.78	117.26	52.99	57.58	57.16	57.98	53.61
Inventory	844.4M	795M	806.9M	878M	967.3M	1.06B	1.02B	1.15B	1.14B	1.08B
Days Inventory Outstanding	106.59	89.87	99.27	110.5	144.92	149.11	136.78	140.13	139.97	139.49
Other Current Assets	0	0	0	0	0	666.9M	16.1M	271.8M	201.1M	199M
Total Non-Current Assets+	16.65B	11.06B	8.81B	8.08B	8.57B	8.35B	6.57B	8.3B	7.98B	7.17B
Property, Plant & Equipment	886.2M	870.1M	833.1M	829.1M	1.03B	1.02B	1.03B	1.14B	1.1B	1.09B
Fixed Asset Turnover	5.20x	6.07x	5.94x	5.71x	3.75x	4.01x	4.01x	3.89x	4.23x	4.00x
Goodwill	5.36B	4.05B	4.18B	4.03B	4.12B	3.1B	3B	3.49B	3.53B	3.32B
Intangible Assets	10.11B	3.51B	3.38B	2.86B	2.99B	2.49B	2.15B	3.29B	2.99B	2.43B
Long-Term Investments	52.4M	2.35B	11.2M	19.5M	0	0	0	0	0	0
Other Non-Current Assets	184.6M	211.9M	398.3M	343.4M	426M	1.71B	377.5M	367.7M	335.2M	318.6M
Total Assets+	19.39B	13.87B	11.63B	10.98B	11.3B	11.49B	10.43B	11.02B	10.81B	9.65B
Asset Turnover	0.24x	0.38x	0.43x	0.43x	0.34x	0.36x	0.40x	0.40x	0.43x	0.45x
Asset Growth %	0.4%	-0.28%	-0.16%	-0.06%	0.03%	0.02%	-0.09%	0.06%	-0.02%	-0.11%
Total Current Liabilities+	2.49B	1.84B	1.44B	1.54B	1.34B	1.38B	1.59B	1.11B	1.59B	1.04B
Accounts Payable	554.9M	471.7M	450.2M	474.9M	520.2M	451.6M	411.2M	537.3M	477.7M	495.2M
Days Payables Outstanding	70.05	53.32	55.39	59.77	77.94	63.56	55.13	65.45	58.6	63.85
Short-Term Debt	0	572.8M	70.4M	190.2M	3.4M	37.3M	603.8M	36.2M	440.6M	36.4M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.02B	0	0	0	0	427.5M	49.1M	-28.4M	0	0
Current Ratio	1.10x	1.53x	1.96x	1.89x	2.04x	2.27x	2.43x	2.44x	1.79x	2.38x
Quick Ratio	0.76x	1.09x	1.40x	1.32x	1.32x	1.50x	1.79x	1.41x	1.07x	1.34x
Cash Conversion Cycle	131.13	117.83	127.33	133.51	184.24	138.53	139.23	131.83	139.35	129.24
Total Non-Current Liabilities+	6.87B	6.08B	4.02B	3.78B	4.16B	4.45B	3.69B	5.06B	4.45B	4.28B
Long-Term Debt	5.99B	5.22B	3.27B	3.05B	3.37B	3.53B	2.92B	4.07B	3.63B	3.58B
Capital Lease Obligations	0	0	0	0	0	132.5M	147.3M	189.5M	0	0
Deferred Tax Liabilities	1.56B	389.9M	321.9M	282.3M	280.6M	276.2M	239.3M	368.2M	262.3M	203.2M
Other Non-Current Liabilities	-685.9M	461.8M	429.5M	443.4M	515.1M	515M	382.8M	433.5M	559.8M	499.2M
Total Liabilities	9.36B	7.91B	5.46B	5.32B	5.5B	5.83B	5.27B	6.18B	6.04B	5.33B
Total Debt+	5.99B	5.8B	3.34B	3.24B	3.37B	3.73B	3.69B	4.32B	4.07B	3.62B
Net Debt	5.57B	5.17B	2.66B	2.69B	3.01B	3.09B	1.83B	3.72B	3.32B	3.06B
Debt / Equity	0.60x	0.97x	0.54x	0.57x	0.58x	0.66x	0.72x	0.89x	0.85x	0.84x
Debt / EBITDA	4.62x	-	3.20x	4.91x	5.90x	5.73x	5.11x	10.36x	7.97x	8.25x
Net Debt / EBITDA	4.30x	-	2.55x	4.08x	5.28x	4.76x	2.53x	8.92x	6.50x	6.97x
Interest Coverage	4.80x	-9.14x	3.45x	1.83x	1.38x	2.08x	3.28x	0.51x	0.87x	0.60x
Total Equity+	10.04B	5.96B	6.17B	5.67B	5.8B	5.66B	5.15B	4.84B	4.77B	4.32B
Equity Growth %	0.15%	-0.41%	0.04%	-0.08%	0.02%	-0.03%	-0.09%	-0.06%	-0.02%	-0.09%
Book Value per Share	71.79	41.57	43.27	40.98	42.52	41.55	38.56	36.00	35.24	31.44
Total Shareholders' Equity	10.04B	5.96B	6.17B	5.67B	5.8B	5.66B	5.15B	4.84B	4.77B	4.32B
Common Stock	8.14B	8.13B	7.89B	7.42B	7.36B	7.12B	7.04B	6.94B	6.84B	6.73B
Retained Earnings	1.91B	-2.1B	-1.98B	-1.84B	-1.7B	-1.86B	-1.93B	-2.07B	-2.08B	-2.25B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-15.5M	-81.8M	253.1M	84.6M	139.4M	395M	35.5M	-27M	10.7M	-162.4M
Minority Interest	-600K	-500K	100K	100K	300K	0	0	0	0	0

Cash Flow

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.2B	654.9M	698.9M	593M	387.8M	636.2M	156.3M	307.3M	405.5M	362.9M
Operating CF Margin %	0.26%	0.12%	0.14%	0.13%	0.1%	0.16%	0.04%	0.07%	0.09%	0.08%
Operating CF Growth %	0.73%	-0.45%	0.07%	-0.15%	-0.35%	0.64%	-0.75%	0.97%	0.32%	-0.11%
Net Income	128M	-4.01B	119.6M	131M	146.1M	-162.6M	-68.9M	-130.9M	-12.7M	-171.8M
Depreciation & Amortization	548.8M	457M	444.8M	423.6M	396.5M	384.8M	312.2M	338.6M	359.5M	325.9M
Stock-Based Compensation	30.3M	23M	43.8M	37.7M	52.2M	58.5M	60.1M	0	68.8M	64.4M
Deferred Taxes	-16.4M	-990.9M	-48.9M	-17.9M	-43.9M	-54.5M	9.4M	-50.5M	-106.6M	9.8M
Other Non-Cash Items	359M	5.28B	243.5M	38M	150.4M	479.2M	138.9M	130.1M	155M	209.3M
Working Capital Changes	147.3M	-101.5M	-103.9M	-19.4M	-313.5M	-69.2M	-295.4M	20M	-58.5M	-74.7M
Change in Receivables	-81.7M	-600K	3.2M	21M	-140.7M	168.9M	-159.7M	100K	-57.1M	-11.1M
Change in Inventory	10.7M	100.7M	-16M	-98.6M	-67M	-170.6M	-2.4M	-76.7M	19.4M	13.7M
Change in Payables	140.6M	-75.7M	-39.6M	28.8M	17M	-2.7M	-7.9M	100.3M	-65.9M	54.2M
Cash from Investing+	-2.65B	-175M	2.34B	-126.8M	-596.1M	-187.8M	1.28B	-1.96B	-77.5M	78.8M
Capital Expenditures	-137M	-106.2M	-88.6M	-102.6M	-137.7M	-170.4M	-152.1M	-96.4M	-101.7M	-118.3M
CapEx % of Revenue	0.03%	0.02%	0.02%	0.02%	0.04%	0.04%	0.04%	0.02%	0.02%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.8M	285M	72.5M	-35.6M	106.8M	-21.7M	-64M	90.5M	24.2M	197.1M
Cash from Financing+	1.52B	-268.7M	-3B	-571.9M	1.8M	-181.1M	-178.7M	421.6M	-187.2M	-611M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-72.2M	-83.2M	-91.1M	-104.9M	-112.4M	-123.9M	-129.6M	-142.4M	-149.7M	-152.5M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-44.7M	-19.6M	-1.8M	-8.7M	-11.2M	-42.9M	-18.5M	-19.6M	-7.3M	-20.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.06B	548.7M	610.3M	490.4M	250.1M	465.8M	4.2M	210.9M	303.8M	244.6M
FCF Margin %	0.23%	0.1%	0.12%	0.1%	0.06%	0.11%	0%	0.05%	0.07%	0.06%
FCF Growth %	1.03%	-0.48%	0.11%	-0.2%	-0.49%	0.86%	-0.99%	49.21%	0.44%	-0.19%
FCF per Share	7.59	3.83	4.28	3.55	1.83	3.42	0.03	1.57	2.25	1.78
FCF Conversion (FCF/Net Income)	9.37x	-0.16x	5.84x	4.53x	2.65x	-3.91x	-2.27x	-2.19x	-31.93x	-2.11x
Interest Paid	0	205.1M	187.6M	133.8M	136.8M	145.8M	133M	0	276.9M	251.4M
Taxes Paid	0	139.5M	186.9M	144.2M	136.2M	81.2M	448M	0	107.5M	155.7M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	1.37%	-50.18%	1.97%	2.21%	2.55%	-2.84%	-1.28%	-2.81%	-0.26%	-3.78%
Return on Invested Capital (ROIC)	4.19%	-11.22%	4.49%	2.06%	1.53%	2.26%	3.91%	0.76%	1.37%	1.09%
Gross Margin	37.19%	38.86%	40.02%	38.71%	37.05%	36.57%	34.22%	32.69%	36.09%	35.27%
Net Margin	2.78%	-75.99%	2.42%	2.77%	3.78%	-3.98%	-1.66%	-3.16%	-0.27%	-3.93%
Debt / Equity	0.60x	0.97x	0.54x	0.57x	0.58x	0.66x	0.72x	0.89x	0.85x	0.84x
Interest Coverage	4.80x	-9.14x	3.45x	1.83x	1.38x	2.08x	3.28x	0.51x	0.87x	0.60x
FCF Conversion	9.37x	-0.16x	5.84x	4.53x	2.65x	-3.91x	-2.27x	-2.19x	-31.93x	-2.11x
Revenue Growth	13.37%	14.7%	-6.33%	-4.34%	-18.21%	5.64%	1.24%	7.56%	4.58%	-6.06%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Consumer Self-Care Americas	-	-	2.43B	2.41B	2.49B	2.69B	2.69B	2.93B	2.96B	2.69B
Consumer Self-Care Americas Growth	-	-	-	-0.75%	3.16%	8.25%	0.00%	8.64%	1.24%	-9.07%
Consumer Self-Care International	-	-	1.49B	1.5B	1.38B	1.4B	1.45B	1.53B	1.69B	1.68B
Consumer Self-Care International Growth	-	-	-	0.33%	-7.60%	0.94%	3.61%	5.54%	10.99%	-0.81%
RX Pharmaceuticals	1.07B	1.04B	969.7M	824.2M	967.5M	975.1M	-	-	-	-
RX Pharmaceuticals Growth	-	-2.19%	-7.01%	-15.00%	17.39%	0.79%	-	-	-	-
Consumer Healthcare	2.75B	2.51B	-	-	-	-	-	-	-	-
Consumer Healthcare Growth	-	-8.83%	-	-	-	-	-	-	-	-
Branded CHC	401.2M	1.65B	-	-	-	-	-	-	-	-
Branded CHC Growth	-	311.81%	-	-	-	-	-	-	-	-
Others	107.7M	78.5M	-	-	-	-	-	-	-	-
Others Growth	-	-27.11%	-	-	-	-	-	-	-	-
Specialty Sciences	344M	-	-	-	-	-	-	-	-	-
Specialty Sciences Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	3.3B	-	-	3.1B	3.23B	3.44B	2.57B	2.87B	2.92B	2.65B
UNITED STATES Growth	-	-	-	-	4.11%	6.68%	-25.43%	11.85%	1.63%	-9.17%
Europe	613.6M	-	-	1.35B	1.34B	1.35B	1.39B	1.47B	1.62B	1.6B
Europe Growth	-	-	-	-	-0.88%	1.11%	3.14%	5.84%	10.05%	-1.10%
Other Geographical Areas	-	-	-	285.8M	276M	271.6M	179.8M	107.3M	116.3M	119.5M
Other Geographical Areas Growth	-	-	-	-	-3.43%	-1.59%	-33.80%	-40.32%	8.39%	2.75%
IRELAND	344M	-	-	25.7M	23.4M	29.8M	23.7M	29.3M	40.8M	39.6M
IRELAND Growth	-	-	-	-	-8.95%	27.35%	-20.47%	23.63%	39.25%	-2.94%

Frequently Asked Questions

Growth & Financials

Perrigo Company plc (PRGO) reported $4.28B in revenue for fiscal year 2024. This represents a 55% increase from $2.76B in 2011.

Perrigo Company plc (PRGO) saw revenue decline by 6.1% over the past year.

Perrigo Company plc (PRGO) reported a net loss of $51.8M for fiscal year 2024.

Dividend & Returns

Yes, Perrigo Company plc (PRGO) pays a dividend with a yield of 7.37%. This makes it attractive for income-focused investors.

Perrigo Company plc (PRGO) has a return on equity (ROE) of -3.8%. Negative ROE indicates the company is unprofitable.

Perrigo Company plc (PRGO) generated $271.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Perrigo Company plc (PRGO) 10-Year Financial Performance & Capital Metrics

PRGO • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

Revenue $4.37B -6.1%
EBITDA $439M -14.2%
Net Income -$172M -1252.8%
EPS (Diluted) -1.25 -1231.2%
Gross Margin 35.27% -2.3%
EBITDA Margin 10.03% -8.7%
Operating Margin 2.58% -20.9%
Net Margin -3.93% -1340.0%
ROE -3.78% -1330.6%
ROIC 1.09% -20.0%
Debt/Equity 0.84 -2.0%
Interest Coverage 0.60 -31.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.5x book value

✗Weaknesses

✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y0.74%

5Y2.48%

3Y1.86%

TTM-2.51%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM67.56%

EPS CAGR

10Y-

5Y-

3Y-

TTM66.89%

ROCE

10Y Avg1.15%

5Y Avg2.13%

3Y Avg1.23%

Latest1.27%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.73B	9.82	30.69	-0.61%	11.72%	16.31%	4.69%	0.62
UPCUniverse Pharmaceuticals Inc.	2.35M	4.17	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	837.58K	0.20	-0.08	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	17.48M	0.47	-0.40	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.07B	15.06	-12.05	-6.06%	-1.21%	-1.17%	11.8%	0.84

Profit & Loss

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	4.6B	5.28B	4.95B	4.73B	3.87B	4.09B	4.14B	4.45B	4.66B	4.37B
Revenue Growth %	0.13%	0.15%	-0.06%	-0.04%	-0.18%	0.06%	0.01%	0.08%	0.05%	-0.06%
Cost of Goods Sold+	2.89B	3.23B	2.97B	2.9B	2.44B	2.59B	2.72B	3B	2.98B	2.83B
COGS % of Revenue	0.63%	0.61%	0.6%	0.61%	0.63%	0.63%	0.66%	0.67%	0.64%	0.65%
Gross Profit+	1.71B	2.05B	1.98B	1.83B	1.43B	1.49B	1.42B	1.46B	1.68B	1.54B
Gross Margin %	0.37%	0.39%	0.4%	0.39%	0.37%	0.37%	0.34%	0.33%	0.36%	0.35%
Gross Profit Growth %	0.18%	0.2%	-0.04%	-0.07%	-0.22%	0.04%	-0.05%	0.03%	0.15%	-0.08%
Operating Expenses+	959.6M	1.39B	1.27B	1.35B	1.26B	1.23B	1.01B	1.38B	1.53B	1.43B
OpEx % of Revenue	0.21%	0.26%	0.26%	0.29%	0.33%	0.3%	0.24%	0.31%	0.33%	0.33%
Selling, General & Admin	771.8M	1.21B	1.15B	1.13B	1.1B	1.11B	1.11B	1.21B	1.27B	1.11B
SG&A % of Revenue	0.17%	0.23%	0.23%	0.24%	0.28%	0.27%	0.27%	0.27%	0.27%	0.25%
Research & Development	187.8M	184M	167.7M	218.6M	119.2M	121.7M	122M	123.1M	122.5M	112.2M
R&D % of Revenue	0.04%	0.03%	0.03%	0.05%	0.03%	0.03%	0.03%	0.03%	0.03%	0.03%
Other Operating Expenses	0	0	10.1M	-6.1M	42.6M	-1.1M	-227.6M	43.3M	131.4M	205M
Operating Income+	747.6M	-2B	598.2M	236.5M	174.7M	265.2M	410.4M	78.9M	151.9M	112.9M
Operating Margin %	0.16%	-0.38%	0.12%	0.05%	0.05%	0.06%	0.1%	0.02%	0.03%	0.03%
Operating Income Growth %	0.32%	-3.67%	1.3%	-0.6%	-0.26%	0.52%	0.55%	-0.81%	0.93%	-0.26%
EBITDA+	1.3B	-1.54B	1.04B	660.1M	571.2M	650M	722.6M	417.5M	511.4M	438.8M
EBITDA Margin %	0.28%	-0.29%	0.21%	0.14%	0.15%	0.16%	0.17%	0.09%	0.11%	0.1%
EBITDA Growth %	0.4%	-2.19%	1.68%	-0.37%	-0.13%	0.14%	0.11%	-0.42%	0.22%	-0.14%
D&A (Non-Cash Add-back)	548.8M	457M	444.8M	423.6M	396.5M	384.8M	312.2M	338.6M	359.5M	325.9M
EBIT	389.5M	-4.63B	453.5M	419.6M	265.5M	133.6M	383.7M	16.9M	165.5M	107.1M
Net Interest Income+	-155.7M	-218.8M	-173.4M	-129M	-126.5M	-127.7M	-125M	-156M	-173.8M	-187.8M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	155.7M	218.8M	173.4M	129M	126.5M	127.7M	125M	156M	173.8M	187.8M
Other Income/Expense	-499.6M	-2.85B	-318.1M	54.1M	-26.7M	-259.3M	-151.7M	-218M	-160.2M	-193.6M
Pretax Income+	248M	-4.85B	280.1M	290.6M	148M	5.9M	258.7M	-139.1M	-8.3M	-80.7M
Pretax Margin %	0.05%	-0.92%	0.06%	0.06%	0.04%	0%	0.06%	-0.03%	-0%	-0.02%
Income Tax+	120.1M	-835.5M	160.5M	159.6M	-10.7M	-38.3M	389.6M	-8.2M	-3.9M	80M
Effective Tax Rate %	0.52%	0.83%	0.43%	0.45%	0.99%	-27.56%	-0.27%	1.01%	1.53%	2.13%
Net Income+	127.9M	-4.01B	119.6M	131M	146.1M	-162.6M	-68.9M	-140.6M	-12.7M	-171.8M
Net Margin %	0.03%	-0.76%	0.02%	0.03%	0.04%	-0.04%	-0.02%	-0.03%	-0%	-0.04%
Net Income Growth %	-0.38%	-32.37%	1.03%	0.1%	0.12%	-2.11%	0.58%	-1.04%	0.91%	-12.53%
Net Income (Continuing)	85M	-4.01B	119.6M	131M	158.7M	44.2M	-130.9M	-130.9M	-4.4M	-160.7M
Discontinued Operations	0	0	0	0	-12.6M	-206.8M	62M	-9.7M	-8.3M	-11.1M
Minority Interest	-600K	-500K	100K	100K	300K	0	0	0	0	0
EPS (Diluted)+	0.91	-28.00	0.84	0.95	1.07	-1.19	-0.98	-0.97	-0.09	-1.25
EPS Growth %	-0.49%	-31.77%	1.03%	0.13%	0.13%	-2.11%	0.18%	0.01%	0.9%	-12.31%
EPS (Basic)	0.92	-28.01	0.84	0.95	1.07	-1.19	-0.98	-0.97	-0.09	-1.25
Diluted Shares Outstanding	139.8M	143.3M	142.6M	138.3M	136.5M	136.1M	133.6M	134.5M	135.3M	137.4M
Basic Shares Outstanding	139.3M	143.26M	142.3M	137.8M	136M	136.1M	133.6M	134.5M	135.3M	137.4M
Dividend Payout Ratio	0.56%	-	0.76%	0.8%	0.77%	-	-	-	-	-

Balance Sheet

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.74B	2.81B	2.82B	2.9B	2.73B	3.13B	3.86B	2.72B	2.83B	2.48B
Cash & Short-Term Investments	417.8M	622.3M	678.7M	551.1M	354.3M	631.5M	1.86B	600.7M	751.3M	558.8M
Cash Only	417.8M	622.3M	678.7M	551.1M	354.3M	631.5M	1.86B	600.7M	751.3M	558.8M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	1.19B	1.18B	1.13B	1.07B	1.24B	593.5M	652.9M	697.1M	739.6M	642.3M
Days Sales Outstanding	94.59	81.29	83.45	82.78	117.26	52.99	57.58	57.16	57.98	53.61
Inventory	844.4M	795M	806.9M	878M	967.3M	1.06B	1.02B	1.15B	1.14B	1.08B
Days Inventory Outstanding	106.59	89.87	99.27	110.5	144.92	149.11	136.78	140.13	139.97	139.49
Other Current Assets	0	0	0	0	0	666.9M	16.1M	271.8M	201.1M	199M
Total Non-Current Assets+	16.65B	11.06B	8.81B	8.08B	8.57B	8.35B	6.57B	8.3B	7.98B	7.17B
Property, Plant & Equipment	886.2M	870.1M	833.1M	829.1M	1.03B	1.02B	1.03B	1.14B	1.1B	1.09B
Fixed Asset Turnover	5.20x	6.07x	5.94x	5.71x	3.75x	4.01x	4.01x	3.89x	4.23x	4.00x
Goodwill	5.36B	4.05B	4.18B	4.03B	4.12B	3.1B	3B	3.49B	3.53B	3.32B
Intangible Assets	10.11B	3.51B	3.38B	2.86B	2.99B	2.49B	2.15B	3.29B	2.99B	2.43B
Long-Term Investments	52.4M	2.35B	11.2M	19.5M	0	0	0	0	0	0
Other Non-Current Assets	184.6M	211.9M	398.3M	343.4M	426M	1.71B	377.5M	367.7M	335.2M	318.6M
Total Assets+	19.39B	13.87B	11.63B	10.98B	11.3B	11.49B	10.43B	11.02B	10.81B	9.65B
Asset Turnover	0.24x	0.38x	0.43x	0.43x	0.34x	0.36x	0.40x	0.40x	0.43x	0.45x
Asset Growth %	0.4%	-0.28%	-0.16%	-0.06%	0.03%	0.02%	-0.09%	0.06%	-0.02%	-0.11%
Total Current Liabilities+	2.49B	1.84B	1.44B	1.54B	1.34B	1.38B	1.59B	1.11B	1.59B	1.04B
Accounts Payable	554.9M	471.7M	450.2M	474.9M	520.2M	451.6M	411.2M	537.3M	477.7M	495.2M
Days Payables Outstanding	70.05	53.32	55.39	59.77	77.94	63.56	55.13	65.45	58.6	63.85
Short-Term Debt	0	572.8M	70.4M	190.2M	3.4M	37.3M	603.8M	36.2M	440.6M	36.4M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	1.02B	0	0	0	0	427.5M	49.1M	-28.4M	0	0
Current Ratio	1.10x	1.53x	1.96x	1.89x	2.04x	2.27x	2.43x	2.44x	1.79x	2.38x
Quick Ratio	0.76x	1.09x	1.40x	1.32x	1.32x	1.50x	1.79x	1.41x	1.07x	1.34x
Cash Conversion Cycle	131.13	117.83	127.33	133.51	184.24	138.53	139.23	131.83	139.35	129.24
Total Non-Current Liabilities+	6.87B	6.08B	4.02B	3.78B	4.16B	4.45B	3.69B	5.06B	4.45B	4.28B
Long-Term Debt	5.99B	5.22B	3.27B	3.05B	3.37B	3.53B	2.92B	4.07B	3.63B	3.58B
Capital Lease Obligations	0	0	0	0	0	132.5M	147.3M	189.5M	0	0
Deferred Tax Liabilities	1.56B	389.9M	321.9M	282.3M	280.6M	276.2M	239.3M	368.2M	262.3M	203.2M
Other Non-Current Liabilities	-685.9M	461.8M	429.5M	443.4M	515.1M	515M	382.8M	433.5M	559.8M	499.2M
Total Liabilities	9.36B	7.91B	5.46B	5.32B	5.5B	5.83B	5.27B	6.18B	6.04B	5.33B
Total Debt+	5.99B	5.8B	3.34B	3.24B	3.37B	3.73B	3.69B	4.32B	4.07B	3.62B
Net Debt	5.57B	5.17B	2.66B	2.69B	3.01B	3.09B	1.83B	3.72B	3.32B	3.06B
Debt / Equity	0.60x	0.97x	0.54x	0.57x	0.58x	0.66x	0.72x	0.89x	0.85x	0.84x
Debt / EBITDA	4.62x	-	3.20x	4.91x	5.90x	5.73x	5.11x	10.36x	7.97x	8.25x
Net Debt / EBITDA	4.30x	-	2.55x	4.08x	5.28x	4.76x	2.53x	8.92x	6.50x	6.97x
Interest Coverage	4.80x	-9.14x	3.45x	1.83x	1.38x	2.08x	3.28x	0.51x	0.87x	0.60x
Total Equity+	10.04B	5.96B	6.17B	5.67B	5.8B	5.66B	5.15B	4.84B	4.77B	4.32B
Equity Growth %	0.15%	-0.41%	0.04%	-0.08%	0.02%	-0.03%	-0.09%	-0.06%	-0.02%	-0.09%
Book Value per Share	71.79	41.57	43.27	40.98	42.52	41.55	38.56	36.00	35.24	31.44
Total Shareholders' Equity	10.04B	5.96B	6.17B	5.67B	5.8B	5.66B	5.15B	4.84B	4.77B	4.32B
Common Stock	8.14B	8.13B	7.89B	7.42B	7.36B	7.12B	7.04B	6.94B	6.84B	6.73B
Retained Earnings	1.91B	-2.1B	-1.98B	-1.84B	-1.7B	-1.86B	-1.93B	-2.07B	-2.08B	-2.25B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-15.5M	-81.8M	253.1M	84.6M	139.4M	395M	35.5M	-27M	10.7M	-162.4M
Minority Interest	-600K	-500K	100K	100K	300K	0	0	0	0	0

Cash Flow

	Jun 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.2B	654.9M	698.9M	593M	387.8M	636.2M	156.3M	307.3M	405.5M	362.9M
Operating CF Margin %	0.26%	0.12%	0.14%	0.13%	0.1%	0.16%	0.04%	0.07%	0.09%	0.08%
Operating CF Growth %	0.73%	-0.45%	0.07%	-0.15%	-0.35%	0.64%	-0.75%	0.97%	0.32%	-0.11%
Net Income	128M	-4.01B	119.6M	131M	146.1M	-162.6M	-68.9M	-130.9M	-12.7M	-171.8M
Depreciation & Amortization	548.8M	457M	444.8M	423.6M	396.5M	384.8M	312.2M	338.6M	359.5M	325.9M
Stock-Based Compensation	30.3M	23M	43.8M	37.7M	52.2M	58.5M	60.1M	0	68.8M	64.4M
Deferred Taxes	-16.4M	-990.9M	-48.9M	-17.9M	-43.9M	-54.5M	9.4M	-50.5M	-106.6M	9.8M
Other Non-Cash Items	359M	5.28B	243.5M	38M	150.4M	479.2M	138.9M	130.1M	155M	209.3M
Working Capital Changes	147.3M	-101.5M	-103.9M	-19.4M	-313.5M	-69.2M	-295.4M	20M	-58.5M	-74.7M
Change in Receivables	-81.7M	-600K	3.2M	21M	-140.7M	168.9M	-159.7M	100K	-57.1M	-11.1M
Change in Inventory	10.7M	100.7M	-16M	-98.6M	-67M	-170.6M	-2.4M	-76.7M	19.4M	13.7M
Change in Payables	140.6M	-75.7M	-39.6M	28.8M	17M	-2.7M	-7.9M	100.3M	-65.9M	54.2M
Cash from Investing+	-2.65B	-175M	2.34B	-126.8M	-596.1M	-187.8M	1.28B	-1.96B	-77.5M	78.8M
Capital Expenditures	-137M	-106.2M	-88.6M	-102.6M	-137.7M	-170.4M	-152.1M	-96.4M	-101.7M	-118.3M
CapEx % of Revenue	0.03%	0.02%	0.02%	0.02%	0.04%	0.04%	0.04%	0.02%	0.02%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	1.8M	285M	72.5M	-35.6M	106.8M	-21.7M	-64M	90.5M	24.2M	197.1M
Cash from Financing+	1.52B	-268.7M	-3B	-571.9M	1.8M	-181.1M	-178.7M	421.6M	-187.2M	-611M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-72.2M	-83.2M	-91.1M	-104.9M	-112.4M	-123.9M	-129.6M	-142.4M	-149.7M	-152.5M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-44.7M	-19.6M	-1.8M	-8.7M	-11.2M	-42.9M	-18.5M	-19.6M	-7.3M	-20.7M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	1.06B	548.7M	610.3M	490.4M	250.1M	465.8M	4.2M	210.9M	303.8M	244.6M
FCF Margin %	0.23%	0.1%	0.12%	0.1%	0.06%	0.11%	0%	0.05%	0.07%	0.06%
FCF Growth %	1.03%	-0.48%	0.11%	-0.2%	-0.49%	0.86%	-0.99%	49.21%	0.44%	-0.19%
FCF per Share	7.59	3.83	4.28	3.55	1.83	3.42	0.03	1.57	2.25	1.78
FCF Conversion (FCF/Net Income)	9.37x	-0.16x	5.84x	4.53x	2.65x	-3.91x	-2.27x	-2.19x	-31.93x	-2.11x
Interest Paid	0	205.1M	187.6M	133.8M	136.8M	145.8M	133M	0	276.9M	251.4M
Taxes Paid	0	139.5M	186.9M	144.2M	136.2M	81.2M	448M	0	107.5M	155.7M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	1.37%	-50.18%	1.97%	2.21%	2.55%	-2.84%	-1.28%	-2.81%	-0.26%	-3.78%
Return on Invested Capital (ROIC)	4.19%	-11.22%	4.49%	2.06%	1.53%	2.26%	3.91%	0.76%	1.37%	1.09%
Gross Margin	37.19%	38.86%	40.02%	38.71%	37.05%	36.57%	34.22%	32.69%	36.09%	35.27%
Net Margin	2.78%	-75.99%	2.42%	2.77%	3.78%	-3.98%	-1.66%	-3.16%	-0.27%	-3.93%
Debt / Equity	0.60x	0.97x	0.54x	0.57x	0.58x	0.66x	0.72x	0.89x	0.85x	0.84x
Interest Coverage	4.80x	-9.14x	3.45x	1.83x	1.38x	2.08x	3.28x	0.51x	0.87x	0.60x
FCF Conversion	9.37x	-0.16x	5.84x	4.53x	2.65x	-3.91x	-2.27x	-2.19x	-31.93x	-2.11x
Revenue Growth	13.37%	14.7%	-6.33%	-4.34%	-18.21%	5.64%	1.24%	7.56%	4.58%	-6.06%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Consumer Self-Care Americas	-	-	2.43B	2.41B	2.49B	2.69B	2.69B	2.93B	2.96B	2.69B
Consumer Self-Care Americas Growth	-	-	-	-0.75%	3.16%	8.25%	0.00%	8.64%	1.24%	-9.07%
Consumer Self-Care International	-	-	1.49B	1.5B	1.38B	1.4B	1.45B	1.53B	1.69B	1.68B
Consumer Self-Care International Growth	-	-	-	0.33%	-7.60%	0.94%	3.61%	5.54%	10.99%	-0.81%
RX Pharmaceuticals	1.07B	1.04B	969.7M	824.2M	967.5M	975.1M	-	-	-	-
RX Pharmaceuticals Growth	-	-2.19%	-7.01%	-15.00%	17.39%	0.79%	-	-	-	-
Consumer Healthcare	2.75B	2.51B	-	-	-	-	-	-	-	-
Consumer Healthcare Growth	-	-8.83%	-	-	-	-	-	-	-	-
Branded CHC	401.2M	1.65B	-	-	-	-	-	-	-	-
Branded CHC Growth	-	311.81%	-	-	-	-	-	-	-	-
Others	107.7M	78.5M	-	-	-	-	-	-	-	-
Others Growth	-	-27.11%	-	-	-	-	-	-	-	-
Specialty Sciences	344M	-	-	-	-	-	-	-	-	-
Specialty Sciences Growth	-	-	-	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	3.3B	-	-	3.1B	3.23B	3.44B	2.57B	2.87B	2.92B	2.65B
UNITED STATES Growth	-	-	-	-	4.11%	6.68%	-25.43%	11.85%	1.63%	-9.17%
Europe	613.6M	-	-	1.35B	1.34B	1.35B	1.39B	1.47B	1.62B	1.6B
Europe Growth	-	-	-	-	-0.88%	1.11%	3.14%	5.84%	10.05%	-1.10%
Other Geographical Areas	-	-	-	285.8M	276M	271.6M	179.8M	107.3M	116.3M	119.5M
Other Geographical Areas Growth	-	-	-	-	-3.43%	-1.59%	-33.80%	-40.32%	8.39%	2.75%
IRELAND	344M	-	-	25.7M	23.4M	29.8M	23.7M	29.3M	40.8M	39.6M
IRELAND Growth	-	-	-	-	-8.95%	27.35%	-20.47%	23.63%	39.25%	-2.94%

Frequently Asked Questions

Growth & Financials

Perrigo Company plc (PRGO) reported $4.28B in revenue for fiscal year 2024. This represents a 55% increase from $2.76B in 2011.

Perrigo Company plc (PRGO) saw revenue decline by 6.1% over the past year.

Perrigo Company plc (PRGO) reported a net loss of $51.8M for fiscal year 2024.

Dividend & Returns

Yes, Perrigo Company plc (PRGO) pays a dividend with a yield of 7.37%. This makes it attractive for income-focused investors.

Perrigo Company plc (PRGO) has a return on equity (ROE) of -3.8%. Negative ROE indicates the company is unprofitable.

Perrigo Company plc (PRGO) generated $271.4M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.